The user facility reported to terumo cardiovascular systems corporation that prior to cardiopulmonary bypass, during prime, they experienced an overspeed message from the system 1 while using the centrifugal pump.The pump head was unattached and reattached, and there was still no flow from the pump.No patient involvement as this occurred during prime.Product was changed out.Surgery was completed successfully.
|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular system in the initial report submitted to the fda on september 17, 2015.(b)(4).Upon evaluation of the device, the complaint was not confirmed.The actual sample was visually inspected upon receipt, finding no anomalies.The sample was circulated at 2000 and 3000 rpm's while varying the back pressure.Pressure readings were taken at 2, 4, 6, and 7l/min flow rates.A centrifugal pump retention sample was taken from lot tg13 and the test was repeated.No anomalies were noted with either sample.A review of the device history record revealed no anomalies.A definitive root cause could not be determined.All available information has been placed on file in quality management for appropriate tracking, trending and follow up.
|